Contact Us   |   Sign In   |   Join CAHR
Board
Share |
Michael Leo, President
Michael Leo has been with Lundbeck Canada for 15 years and is currently the Senior Manager, Market Access for Federal, ON & West public payers. Previous roles at Lundbeck include regional and district sales management as well as product management assignments in Canada and public affairs at Lundbeck's global headquarters in Denmark. Mike has held numerous other positions in the pharmaceutical industry at SmithKline Beecham, HoechstMarionRoussel and Searle. Mike has been a member of the Board of Directors of the Canadian Association for Healthcare Reimbursement for five years and is a former board member of the Government Relations Institute of Canada (GRIC). Mike holds an MBA from the University of Ottawa and a B.Com from Carleton University, and is a 2018 CMAP (Certified Market Access Professional) graduate.
Michael Leo
Ferg Mills, Vice President
Ferg Mills is a health economist and Director of Strategic Consulting at Innomar Strategies, where he heads the HEOR team. Ferg's academic interests focus on Canadian pharmaceutical policy, in particular on HTA processes and institutions. Ferg's areas of expertise include decision analytic modeling, clinical trial analysis and budget impact analysis, and he regularly presents at industry events on these subjects. Ferg's team develops reimbursement strategies and submission dossiers for the Common Drug Review and the Pan-Canadian Oncology Drug Review. Ferg holds a BA in Economics from the University of Toronto and a MSc in Health Economics from the University of York.
Ferg Mills
Julia Brown, Immediate Past President
Julia has been with Janssen Inc. for 14 years and is currently the Vice President of Government Affairs and Market Access. Previous roles at Janssen include National Director of Government and Community Relations, Director of Health Economics and Reimbursement and Director of Government Relations, Ontario/Atlantic. Julia also serves as the President of the Canadian Association for Healthcare Reimbursement (CAHR) and been a member of the CAHR Board of Directors for 11 years. She served as a Chief of Staff in the Ontario Provincial Government from 1997 to 2003 in the portfolios of Municipal Affairs and Housing, Management Board and Natural Resources. Julia has additional experience in the Federal Government, the not-for-profit sector and textile manufacturing and holds a B.A. in Political Science from Carleton University. She resides in Toronto with her three daughters and enjoys skiing, golfing and travel.
Julia Brown
Rebecca Vieria, Secretary-Treasurer
Rebecca Szilagyi-Vieria has recently taken on a new role as the Manager of Pricing and Trade Strategy for GlaxoSmithKline. Prior to this Rebecca lead the Strategic Consulting Team at Innomar Strategies where her focus was obtaining optimal access for clients by developing strong market access strategies focusing on pricing, reimbursement and patient assistance programs. She has experience working in primary care, specialty drugs, oncology and orphan diseases.

Rebecca began her career in pharmacovigilance for consumer health products before moving on to the federal government. She held roles as an economist with the PMPRB and as a regulatory analyst within Health Canada. She has been a volunteer with CAHR for three years and holds a Masters degree in Public Health Policy and a B.Sc. in Biomedical Science.
Rebecca Szilagyi-Vieria
Matthew Brougham, Director at Large
Matthew specialises in scientific, economic and financial analysis essential for efficient and equitable resource allocation. He has applied this expertise to the health sector (in particular, drug plan management), tax and transfer policy, transport, and fisheries management and been an analyst/advisor and/or decision maker within public sector agencies since 1988. His professional background includes senior government positions in New Zealand and Canada including Vice President of CADTH (Canada's health technology assessment agency) and Chief Executive of PHARMAC (New Zealand’s universal drug plan).

Matthew holds science degrees in Zoology (University of Otago, NZ) and Natural resource management (Canterbury University, NZ) and a post graduate diploma in Health Economics (University of Tromso, Norway). His continuing professional education has focused on evaluation techniques, and business management and leadership.
Matthew Brougham
Bill Dempster, Director, Events & Education
As CEO of 3Sixty Public Affairs, Bill Dempster develops and implements high-impact government relations, policy and strategies for clients in the health and life sciences sector. Bill draws on his business, legal, non-profit and government experience to help clients find mutually beneficial solutions to complex regulatory, reimbursement and policy problems. Previously, Bill was a member of the federal relations and health policy team at Pfizer Canada. His experience also includes working for a Member of Parliament, the United Nations and major Canadian law firms. Bill is fluently bilingual, and has degrees in history (King's College, University of Western Ontario), law (Queen's University), and a Masters of Arts in international affairs (Norman Paterson School of International Affairs, Carleton University). He was called to the Bar of Ontario in 2002.
Bill Dempster
Stephen Filbey, Director at Large
As Founder and Principal Consultant at WestPAR Consultancy Inc., Stephen helps organizations solve the unique reimbursement, access and policy challenges of Western Canada. He is an accomplished professional who leverages his 30 years of experience in the pharmaceutical industry to develop solutions through innovation, partnership, consensus-building and trust.

Over the 10 most recent years, Stephen has guided more than 45 clients in developing and implementing Reimbursement, Market Access, Advocacy and Policy Strategies throughout Western Canada. His experience spans a wide range of therapeutic areas in rare disease, oncology, non-oncology and medical devices. Stephen holds a Bachelor's degree in Science from the University of Windsor and a one-year, non-accredited Continuing Medical Education & Needs Assessment Internship through the Department of CME at the University of Calgary.
Stephen Filbey
Laura Fitzgerald, Director at Large
Laura Fitzgerald began working with Pfizer Canada in 1989 as a sales representative within its first sales division. Since that time, she has worked in both pharmaceuticals and medical devices, in progressive positions of responsibility and leadership. Her experience has been both as an employee of major firms (i.e. Pfizer Canada Inc., J&J Medical Devices, Teva Canada Innovation) and as a consultant lobbyist for multiple organizations. In 1997, Laura moved from sales to work in government and public affairs, which was a specialty area of emerging importance to the success of Canadian pharmaceutical companies. She has since specialized in Canadian market access and its challenges, studied and worked on various health policies, engaged with western governments and their respective staff, enjoyed stakeholder engagement and participated in business development.
Laura Fitzgerald
Brent Korte, Director at Large
Brent has more than 25 years of experience in the healthcare and pharmaceutical industry. He has both national and regional expertise in health policy, government relations, market access, strategy development and implementation expertise across the country. Brent has led teams, mentored leaders and executes product development, listing agreements, advocacy and government relations strategies that get results. He also has multi-therapeutic experience and expertise in oncology, immunology, biologics, and biosimilars.
Brent is known as a consensus-builder who establishes constructive partnerships with pharmaceutical stakeholders while building trusting business relationships. As a Health Policy Consultant, Brent provides strategic advice related to commercialization, stakeholder/government relations, corporate communications strategy and PLA implementation.

Brent graduated from the University of Alberta and is an active volunteer in the local community and has a been a long-time member of the coaching team at the U of A Golden Bears football club.
Brent Korte
Hélène Lalonde, Director at Large
Hélène has more than 10 years of experience as a Market Access and Reimbursement Professional and is currently leading the market access and pricing functions at Pendopharm, specialized in innovative medicine and leading a team of market access professionals. This role has allowed her to gain expertise in a highly diversified range of products. Hélène also has extensive experience in helping develop business models to in-license existing molecules. As such, the assessment of business opportunities for Canada is a key component of her daily work. She is also responsible for all activities related to CADTH/INESSS, PMPRB, pCPA/PLA negotiations, and public/private payers. Her previous work experience includes market access, sales and marketing roles with GSK and Novartis. Hélène is a bilingual (English/French) registered pharmacist in the province of Quebec.
Hélène Lalonde
James LeBrocq, Director, Membership
James is presently Senior Manager Marketing and Business Development at McKesson Canada, with a focus on the Specialty Division, a position he has held for the past six years. James spent seven years on the Board of Directors at CAHR, as Director for Membership, taking a break in 2014. James helped initiate the Market Access 101 program at CAHR, and led the CMAP initiative, and has been involved recently at CAHR on the Advisory Board. James has over 25 years' experience in the pharmaceutical industry with firms like AmerisourceBergen, Schering Plough, Aventis as well as 15 years at Innomar/AmersourceBergen prior to his role at McKesson.
James LeBrocq
Mark Levine, Director, Communications
Mark Levine is Director, Strategic Information Services (SIS) at IQVIA where he is responsible for the planning, editorial management and production of SIS products and services, including PharmaFocus, Provincial Reimbursement Advisor (PRA Weekly and Quarterly), Monthly Market Monitor, The Weekly Capsule, and related client briefings and events.

Mark is a communications professional with more than 20 years of practice within the broader health care community. He has worked with a diverse spectrum of health-related organizations including Community Care Access Centres in Ontario, the Canadian Diabetes Association and Canada Health Infoway. He has extensive experience in strategic planning and development, change management, stakeholder and client relations, marketing, publishing, editing, media relations and web technologies, and has counselled Boards, senior executives and front-line employees in strategic communications planning and best practices. A former journalist, Mark has also written for major Canadian newspapers and was managing editor, then publisher, of the Journal of the Ontario Dental Association.
Mark Levine
Arvind Mani, Director at Large
Arvind Mani is Managing Director at Mani & O'Quinn Reimbursement Strategy Experts (MORSE) Consulting Inc. – a consultancy focused on developing creative solution for challenging reimbursement problems. Arvind has more than 20 years of work experience in industry, associations (pharmaceutical and pharmacy), and consulting. He has an in-depth understanding of pharmaceutical industry issues and is continually looking for opportunities to shed light on emerging issues of importance to the pharmaceutical market access community (e.g. public and private payer product listing agreements, international experience with biosimilars, orphan drugs, etc.). Arvind has the ability to establish positive and constructive relationships with pharmaceutical stakeholders through a strong sense of integrity and trust.
Arvind Mani
Angela Rocchi, Director at Large
Angela Rocchi is the founder and principal of Athena Research.  Angela has designed and conducted health economic research for the Canadian pharmaceutical industry since 1990.  She has pursued independent research on pragmatic, highly relevant issues in the Canadian environment, including the role of economic evidence in Canadian reimbursement decision-making and the performance of the Canadian HTA agencies – CDR, INESSS and pCODR – as well the pCPA. She is a past-President of the Canadian Association for Population Therapeutics and a current board member of the Canadian Association for Healthcare Reimbursement.
Angela Rocchi
Myra Wang, Director at Large
Myra Wang is a Clinical Epidemiologist within the Evidence Development and Standards branch at Health Quality Ontario. In her role, she conducts clinical evidence reviews and health technology assessments on non-drug health technologies to support evidence-based decision-making, including recommendations on whether a particular health technology should be publicly funded in Ontario. In addition, she has helped develop other provincial evidence-based products such as clinical handbooks and quality standards. Myra also worked at the Institute for Clinical Evaluative Sciences on health services research focused on the use of electronic medical record data, and at other institutions on primary research projects. Myra holds a BSc in Anatomy and Cell Biology from McGill University, and a MSc in Pharmaceutical Sciences from the University of British Columbia.
Myra Wang
Membership Software Powered by YourMembership  ::  Legal